The intradermal injections market in Asia Pacific is expected to grow from US$ 774.05 million in 2021 to US$ 1,698.43 million by 2028. It is estimated to grow at a CAGR of 11.9% from 2021 to 2028.
Health systems in developing economies focus on introducing various advanced therapeutic, diagnostic, and aesthetic technologies into their service portfolios to be able to provide healthcare facilities with high efficiency. In developed countries, intradermal devices have received significant acceptance in vaccination and cosmetic procedures. In developing countries, although these devices are mainly used in vaccination, tuberculosis diagnosis, and aesthetic procedures, the market is currently in a nascent stage of development. Many developing countries are attractive destinations for medical tourism, especially for aesthetic procedures due to the lower costs of these procedures than developed countries. Health facilities, medical spas, and wellness centers in developing countries are increasingly offering a comprehensive range of inexpensive but high-quality medical-aesthetic procedures, which, eventually, triggers the demand for intradermal injections. The leading manufacturers of intradermal injections are developing ideal devices and collaborating with other players to improve the therapeutic efficacy of existing and new drugs. Asia Pacific is expected to be the fastest-growing market for intradermal injections among all major regions, with countries such as China, Japan, India, and South Korea being prime contributors to the market growth, during the forecast period. The rapid pace of urbanization, surging investments by healthcare providers in improving infrastructure, growing awareness among the population, and increasing availability of a range of advanced products and technologies are all contributing to the growth of this market.
The Asia Pacific intradermal injections market, by end user, is segmented into hospitals, diagnostic laboratories, academics and research institutes, and others. The hospitals segment held the largest market share in 2021.
Developed and Developing Countries Provide Significant Growth Opportunities to Market
Health systems in developing economies focus on introducing various advanced therapeutic, diagnostic, and aesthetic technologies into their service portfolios to be able to provide healthcare facilities with high efficiency. In developed countries, intradermal devices have received significant acceptance in vaccination and cosmetic procedures. In developing countries, although these devices are mainly used in vaccination, tuberculosis diagnosis, and aesthetic procedures, the market is currently in a nascent stage of development. Many developing countries are attractive destinations for medical tourism, especially for aesthetic procedures due to the lower costs of these procedures than developed countries. Health facilities, medical spas, and wellness centers in developing countries are increasingly offering a comprehensive range of inexpensive but high-quality medical-aesthetic procedures, which, eventually, triggers the demand for intradermal injections. The leading manufacturers of intradermal injections are developing ideal devices and collaborating with other players to improve the therapeutic efficacy of existing and new drugs. Asia Pacific is expected to be the fastest-growing market for intradermal injections among all major regions, with countries such as China, Japan, India, and South Korea being prime contributors to the market growth, during the forecast period. The rapid pace of urbanization, surging investments by healthcare providers in improving infrastructure, growing awareness among the population, and increasing availability of a range of advanced products and technologies are all contributing to the growth of this market.
Market Overview
The Asia Pacific intradermal injections market is segmented into Australia, China, India, Japan, South Korea, and Rest of Asia Pacific. The market growth in the region is ascribed to the growing investments from international players in China and India with greater government support, expanding base of CRO service providers, and advancements in healthcare infrastructure. The medical device industry in China has grown at a faster pace in the past several years. This growth can be attributed to China’s 13th Five-Year Plan that prioritizes health and innovation, increased demand for technologically advanced medical devices, significantly rising geriatric population, and growing chronic health conditions among people. In addition, the availability of low-cost and skilled laborers and massive space for production facilities have encouraged various market leaders to have their production plants in China. The Population Reference Bureau has projected that 366 million people in China will be aged 65 or more by 2050. Per the WHO’s Ageing and Health in China, in 2019, ~75% of people with age 60 and above suffered from noncommunicable diseases, such as cardiovascular disease, diabetes, and hypertension. The R&D sector of China is focused on develop devices for painless delivery of drugs via intradermal route, which can specifically of help during the procedures involving elderly populations.Asia Pacific Intradermal Injections Market Segmentation
The Asia Pacific intradermal injections market is segmented on the basis of method, application, end user, and country.- Based on method, the market is segmented into normal sized needle, short needle, and without needle. The normal sized needles segment registered the largest market share in 2021. The normal sized needles segment is further subsegmented into intradermal microinjections, microneedle arrays, and tattoo devices. The short needle segment is bifurcated into intradermal liquid jet injectors and ballistic intradermal injectors.
The Asia Pacific intradermal injections market, by end user, is segmented into hospitals, diagnostic laboratories, academics and research institutes, and others. The hospitals segment held the largest market share in 2021.
- Based on country, the market is segmented into Australia, China, India, Japan, South Korea, and rest of Asia Pacific. China dominated the market share in 2021.
Table of Contents
1. Introduction
3. Research Methodology
4. APAC Intradermal Injections Market Landscape
5. APAC Intradermal Injections Market - Key Market Dynamics
6. Intradermal Injections Market- APAC Analysis
7. APAC Intradermal Injections Market Revenue And Forecasts To 2028- By Method
8. APAC Intradermal Injections Market Revenue and Forecasts To 2028 - Application
9. APAC Intradermal Injections Market Analysis - End User
10. APAC Intradermal Injections Market Revenue and Forecasts To 2028 - Country Analysis
11. Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned
- Bd.
- West Pharmaceutical Services, Inc.
- Terumo Corporation.
- Nanopass.
- Pharmajet.
- Idevax.
- Eunsung Global.
- Crossject.
- Cardinal Health Inc.
- Hindustan Syringes And Medical Devices Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 138 |
| Published | November 2022 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( $ | $ 774.05 Million |
| Forecasted Market Value ( $ | $ 1698.43 Million |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Asia Pacific |
| No. of Companies Mentioned | 10 |
